These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 18755367)

  • 1. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the tumor necrosis factor antagonists.
    Bachmann F; Nast A; Sterry W; Philipp S
    Semin Cutan Med Surg; 2010 Mar; 29(1):35-47. PubMed ID: 20430306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
    Breedveld FC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of TNF-α antagonists on the quality of life in selected skin diseases.
    Gisondi P; Girolomoni G
    G Ital Dermatol Venereol; 2013 Jun; 148(3):243-8. PubMed ID: 23670060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha inhibitors in dermatology.
    Cordoro KM; Feldman SR
    Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
    Gomez-Reino JJ; Carmona L;
    Arthritis Res Ther; 2006; 8(1):R29. PubMed ID: 16507128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.